Oncology

Trastuzumab pamirtecan (BNT323/DB-1303) displayed enhanced progression-free survival (PFS) vs ado-trastuzumab emtansine (T-DM1; Kadcyla) in patients w...

According to Sundar Jagannath, MBBS, the cure for multiple myeloma has been observed in the 12 patients who participated in the phase 1b/2 CARTITUDE-1...

According to Denise B. Reynolds, RD, registered dietitian at Atrium Health Levine Cancer, smaller and more frequent meals may help mitigate the occurr...

The latest screening algorithm for the Shield™ blood test (Shield V2) demonstrated positive sensitivity and specificity outcomes in the detection of c...

A deep conversation accounting for a patient’s medical characteristics and their goals for treatment dictates which tyrosine kinase inhibitor (TKI) Jo...

Study design and data source The CKD-PC is an international consortium established to provide evidence that can improve the prevention and management...

Ruxolitinib has been used as a therapy for myelofibrosis for approximately 15 years, as of 2025. According to Francesca Palandri, MD, PhD, it has demo...

Subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) significantly reduced the risk of disease progression or death compared with active...

As multiple myeloma treatment has evolved throughout the years, oncologists are now closer than ever to saying they have a “cure” for the disease, not...

The addition of benmelstobart (TQB2450) to anlotinib (Fukewei) exhibited advantageous progression-free survival (PFS) outcomes vs sunitinib (Sutent) i...